Urinary 11-dehydro thromboxane B2 levels in type 2 diabetic patients before and during aspirin intake

Abstract

Regardless of the mechanisms related to aspirin non-responsiveness, most patients enrolled in the present study also presented a reduced or minimal response to low-dose aspirin therapy, thereby indicating a clear variability related to aspirin effectiveness. Moreover, BMI appears to be independently associated to the reduction of urinary 11-dhTXB₂ concentrations in type 2 diabetic patients taking aspirin.

Should diabetes still be considered a coronary artery disease equivalent?

“…[48][49][50][51] Another meta-analysis found a borderline significant reduction in major adverse coronary events but not in mortality. 52 The lack of efficacy of aspirin in diabetic patients compared to those with CAD may be due to resistance to the effects of aspirin in diabetic patients, [53][54][55] resulting in residual thrombogenic risk. 56 In summary, the data on aspirin illustrate the case that even though diabetes might be associated with a similar risk to MI, this does imply that any treatment modality would be equally effective.…”

Platelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery disease

“…Currently, ASA is largely prescribed for the primary prevention of cardiovascular events in DM but the evidence supporting its efficacy is surprisingly scarce and controversial [14][15][16] . Recent observations demonstrate that healthy subjects and DM patients with poor ASA response not only seem to manifest an incomplete inhibition of COX-1, but also display a pro-inflammatory milieu and enhanced oxidative stress [17][18][19] . On the other hand, diet-induced weight loss in subjects with central obesity reduced platelet reactivity and restored platelet sensitivity to nitric oxide, prostacyclin, and physiologic anti-aggregating agents.…”